Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2016

View Archived Issues

Acceleron initiates phase II study of ACE-083 in facioscapulohumeral muscular dystrophy

Novel drug targets described at the ACR/ARHP annual meeting

Regulus unveils new drug development candidates

FDA grants orphan drug designation to VK-0214 for X-linked adrenoleukodystrophy

Cristal Therapeutics, iTeos Therapeutics to develop immuno-oncology products

Dosing begins in phase III program of ReVance Therapeutics' daxibotulinumtoxinA

Aclaris Therapeutics clear to begin phase I testing of ATI-50001

Abivax provides update on clinical development program for ABX-464

Blisibimod BRIGHT-SC study demonstrates positive trends in the week 48 analysis

Arcturus Therapeutics announces collaboration with Takeda Pharmaceutical

First patient dosed in phase II/III trial of 18F-DCFPyL imaging agent

First-in-human data reported for Merck KGaA's bifunctional immunotherapy antibody

Cabozantinib meets endpoints in phase II lung cancer study

FDA and European approvals granted to begin clinical testing of Lyme disease vaccine candidate

Phase III STEADFAST study of Actimmune does not meet primary endpoint

Novel bispecific antibody NI-1701 active in B-cell cancer models

AL-S Pharma created to develop innovative therapy for patients with ALS

AstraZeneca and Lilly enter agreement for second drug for Alzheimer's

Gilead Sciences submits NDA for sofosbuvir/voxilaprevir/velpatasvir

MicroRNA identified as diagnostic, prognostic biomarker in acute myocardial infarction

EMA accepts for review MAA for dupilumab in atopic dermatitis

Cadila Healthcare discloses new kappa-opioid receptor agonists

BioHaven Pharmaceutical's BHV-0223 granted orphan drug status in U.S. for ALS

Universite de Geneve patents 5-aminolevulinic acid derivatives

ChemoCentryx describes novel C-C chemokine receptor type 2 ligands

Forge Therapeutics and Evotec enter strategic alliance to develop novel LpxC inhibitors

Voyager presents positive interim results from phase Ib trial of VY-AADC01

Amicus Therapeutics reports data from phase I/II study of ATB-200/AT-2221

European Commission grants conditional marketing authorization for Venclyxto

FDA grants orphan status to RPGR gene therapy for retinitis pigmentosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...